ENGN — enGene Therapeutics Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1980845 · Quebec, Canada
Last close
$1.72
Market Cap
$115.27M
52W High
$12.25
52W Low
$1.40
ADV30
1,467,694
Next earnings
2026-12-22

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jul 2026 0 — -34,014,000 -32,501,000 288,322,000 41,025,000 58,032,000
Apr 2026 0 — -31,968,000 -30,227,000 307,524,000 29,827,000 52,356,000
Jan 2026 0 — -31,185,000 -29,752,000 337,113,000 36,613,000 55,567,000
Oct 2025 0 — -39,481,000 -37,880,000 221,468,000 50,152,000 53,758,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-103,309,000
Investing CF
$-32,038,000
Financing CF
$143,748,000
CapEx
$-1,392,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.91
As of
2026-09-13

Balance + Analyst (yfinance extras)

Retained Earnings
$-464,512,000
Inventory
—
Receivables
$975,000
ST Investments
$225,295,000
EBIT TTM
$-127,787,000
Pretax Income TTM
$-130,857,000
Interest Exp TTM
$3,070,000
Analysts
7

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Oct 2025 0 -123,165,000 -117,302,000 221,468,000 53,758,000 167,710,000 -99,239,000
Oct 2024 0 -62,297,000 -55,142,000 311,173,000 38,561,000 272,612,000 -48,281,000
Oct 2023 0 -26,060,000 -99,917,000 86,959,000 14,473,000 72,486,000 -24,743,000
Oct 2022 0 -19,427,000 -24,462,000 23,909,000 47,405,000 -23,496,000 -17,592,000

TTM Snapshot

Revenues TTM
$-9,779,000
NetIncome TTM
$130,360,000
OpCashFlow TTM
—
Assets (Latest)
$288,322,000
Forward EPS
$-1.44

Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.00 · spot: $1.85 · call volume: 109 · put volume: 4,116
Expected Move to 2027-03-19: ±$0.80 (43.24%) — implied range $1.05 – $2.65 · ATM straddle on $2.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CRDL Cardiol Therapeutics Inc. $113.53M $0.97 —
LENZ LENZ Therapeutics, Inc. $109.97M $3.50 —
MOLN MOLECULAR PARTNERS AG $109.55M $2.86 —
CMPX Compass Therapeutics, Inc. $109.26M $0.61 —
FATE FATE THERAPEUTICS INC $124.00M $1.02 —

News headlines (Yahoo Finance, 1h cache)

EnGene Therapeutics (ENGN) Stock Gets Fair Value Boost After Analyst Views On LEGEND Data
2026-11-14 22:08 · Yahoo
Update: enGene Shares Rise After Updating Pivotal Bladder Cancer Data
2026-11-12 19:17 · Yahoo
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
2026-11-11 21:01 · Yahoo
enGene to Participate in Upcoming Investor Conferences
2026-11-06 13:00 · Yahoo
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
2026-10-16 05:02 · Yahoo
enGene to Host KOL Webinar on October 15, 2026
2026-10-13 12:00 · Yahoo
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-09-08 11:30 · Yahoo
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
2026-08-13 15:07 · Yahoo
Neumora depression drug fails; EnGene to cut 50% of staff
2026-06-16 09:08 · Yahoo
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
2026-11-11 21:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.